Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): A randomized controlled trial

Journal of Internal Medicine

Volumn 278, Issue 1, 2015, Pages 59-67

  Neukamm, A ^a,b   Hoiseth A D ^a,b   Einvik, G ^a,b   Lehmann, S ^c,d   Hagve, T A ^a,b   Soyseth V ^a,b   Omland, Torbjørn ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Chronic obstructive pulmonary disease; Endothelial function; Hydroxymethylglutaryl CoA reductase inhibitors; Inflammation; Pulmonary disease; Randomized controlled trial

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; PYRIMIDINES; SULFONAMIDES;

AGED; ARTICLE; ASTHMA; BLOOD VESSEL FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPEREMIA; HYPERTENSION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NORWAY; OUTCOME ASSESSMENT; PERIPHERAL ARTERIAL TONOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LUNG; METABOLISM; PHYSIOPATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; FORCED EXPIRATORY VOLUME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-6; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIMIDINES; SULFONAMIDES; VITAL CAPACITY;

EID: 84930924025     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12337     Document Type: Article

References (35)

1. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence Thorax 2010; 65: 930-6.
2. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982-8.
3. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45: 291-300.
4. Sin DD, MacNee W. Chronic obstructive pulmonary disease and cardiovascular diseases: a 'vulnerable' relationship. Am J Respir Crit Care Med 2013; 187: 2-4.
5. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-41.
6. Pedersen TK, Berg K, Haghfelt T et al. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
7. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001-9.
8. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
9. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
10. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29: 279-83.
11. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554-60.
12. Chen YJ, Chen P, Wang HX et al. Simvastatin attenuates acrolein-induced mucin production in rats: involvement of the Ras/extracellular signal-regulated kinase pathway. Int Immunopharmacol 2010; 10: 685-93.
13. Kim SE, Thanh Thuy TT, Lee JH et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med 2009; 41: 277-87.
14. Zeki AA, Franzi L, Last J, Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 2009; 180: 731-40.
15. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
16. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
17. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
18. Anderson TJ, Uehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
19. Hamburg NM, Keyes MJ, Larson MG et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117: 2467-74.
20. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2007; 115: 2390-7.
21. Thomsen M, Ingebrigtsen TS, Marott JL et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013; 309: 2353-61.
22. Ferrari R, Tanni SE, Caram LM, Correa C, Correa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res 2013; 14: 24.
23. Dahl M, Vestbo J, Lange P. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-5.
24. Lahousse L, Loth DW, Joos GF et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013; 26: 212-7.
25. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-5.
26. Kaczmarek P, Sladek K, Skucha W et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 2010; 120: 11-7.
27. Criner GJ, Connett JE, Aaron SD et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-10.
28. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
29. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
30. Leung BP, Sattar N, Crilly A et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003; 170: 1524-30.
31. Xu H, Liu P, Liang L et al. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006; 54: 3441-51.
32. Celli BR, Locantore N, Yates J et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065-72.
33. Agusti A, Edwards L, Rennard S. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012; 7: e3y483.
34. Stone NJ, Robinson J, Lichtenstein AH et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014; 129: S1-45.
35. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 98: 1055-62.